Investors position for Q2 earnings beat as Zacks highlights ISRG strength
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.06B | $8.35B | $7.12B | $6.22B | $5.71B | $4.36B | $4.48B | $3.72B |
| Cost of Revenue | $3.41B | $2.72B | $2.39B | $2.03B | $1.75B | $1.50B | $1.37B | $1.12B |
| Gross Profit | $6.66B | $5.63B | $4.73B | $4.20B | $3.96B | $2.86B | $3.11B | $2.60B |
| Gross Margin | 66.13% | 67.46% | 66.39% | 67.44% | 69.32% | 65.65% | 69.45% | 69.92% |
| Operating Expenses | $3.71B | $3.29B | $2.96B | $2.62B | $2.14B | $1.81B | $1.74B | $1.40B |
| Operating Income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B | $1.05B | $1.37B | $1.20B |
| Operating Margin | 29.27% | 28.12% | 24.80% | 25.35% | 31.89% | 24.09% | 30.69% | 32.21% |
| Net Income | $2.86B | $2.32B | $1.80B | $1.32B | $1.70B | $1.06B | $1.38B | $1.13B |
| Net Margin | 28.38% | 27.81% | 25.24% | 21.25% | 29.85% | 24.33% | 30.80% | 30.29% |
| EPS (Basic) | $8.00 | $6.54 | $5.12 | $3.72 | $4.79 | $3.02 | $3.98 | $3.31 |
| EBITDA | N/A | $2.81B | $2.17B | $1.94B | $2.13B | $1.33B | $1.58B | $1.32B |
| Stock Option Compensation Expense | N/A | $676.80M | $598.20M | $513.20M | $449.20M | $395.40M | $335.80M | $261.20M |
| Price To Earnings Ratio | N/A | 79.82 | 65.90 | 71.38 | 75.06 | 90.25 | 49.46 | 48.28 |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | $185.40B | $118.48B | $94.38B | $127.95B | $95.72B | $68.22B | $54.45B |